My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

15.13 +0.17 (+1.17%)

Streaming Delayed Price Updated: 2:07 PM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >

IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday ↗

September 12, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics ↗

June 04, 2025

China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma.

Via Stocktwits

Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday ↗

April 01, 2025

Via Benzinga

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength ↗

March 19, 2025

Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, driven by Fruzaqla sales and new regulatory approvals in China.

Via Benzinga

Earnings Scheduled For March 19, 2025 ↗

March 19, 2025

Via Benzinga

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million ↗

January 02, 2025

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025.

Via Benzinga

Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday ↗

November 20, 2024

Via Benzinga

Hutchmed scores U.S. success with cancer drug, but profits still dip ↗

August 15, 2024

Key Takeaways: Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by uptake of the cancer drug Fruzaqla The company plans to focus on innovative drugs...

Via Benzinga

Why HUTCHMED Stock Is Moving Higher Friday ↗

July 05, 2024

HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status.

Via Benzinga

Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday ↗

May 09, 2024

Via Benzinga

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

March 14, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.

Via Benzinga

Topics Stocks

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 13, 2024

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 13, 2024

Via Benzinga

Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket ↗

March 13, 2024

Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-quarter financial results.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

March 13, 2024

Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning!

Via InvestorPlace

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

March 13, 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.

Via Benzinga

Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

February 14, 2024

U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday.

Via Benzinga

Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets ↗

February 03, 2024

Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.

Via Talk Markets

Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 24, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know ↗

November 10, 2023

Via Benzinga

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗

November 08, 2023

On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.

Via Investor's Business Daily

Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗

November 02, 2023

On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗

October 30, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 30, 2023

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

Via Benzinga

Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗

October 27, 2023

A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday ↗

October 27, 2023

U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 24, 2023

A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition